Broadview Ventures

Type

Venture Capital

Status

Active

Location

Boston, United States

Total investments

73

Average round size

7M

Portfolio companies

53

Rounds per year

4.56

Lead investments

8

Follow on index

0.27

Exits

6

Stages of investment
SeedPrivate EquityEarly Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaClinical Trials

Summary

Broadview Ventures appeared to be the VC, which was created in 2008. The leading representative office of defined VC is situated in the Boston. The fund was located in North America if to be more exact in United States.

Comparing to the other companies, this Broadview Ventures performs on 17 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. Deals in the range of 1 - 5 millions dollars are the general things for fund. When the investment is from Broadview Ventures the average startup value is 5-10 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Broadview Ventures, startups are often financed by Boulder Ventures, Atlas Venture, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Boulder Ventures, Atlas Venture, Amgen Ventures. In the next rounds fund is usually obtained by Remeditex Ventures, Boulder Ventures, Atlas Venture.

Among the most popular portfolio startups of the fund, we may highlight 480 Biomedical, Capricor Therapeutics, InfoBionic. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The fund was created by Christopher Colecchi. The overall number of key employees were 6.

Show more

Investor highlights

Industry focus
MedtechBiotech/Life SciencesMedtechHealthcare
Stage focus
SeedSeries A
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
73
Lead investments
8
Exits
6
Rounds per year
4.56
Follow on index
0.27
Investments by industry
  • Health Care (51)
  • Biotechnology (47)
  • Medical Device (35)
  • Therapeutics (21)
  • Medical (17)
  • Show 23 more
Investments by region
  • United States (52)
  • France (2)
  • Switzerland (3)
  • Canada (4)
  • Denmark (4)
  • Show 4 more
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
14M
Group Appearance index
0.55
Avg. company exit year
10
Avg. multiplicator
6.98
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
CroíValve 04 Feb 2022 Medical Device Early Stage Venture 9M County Dublin, Dublin, Ireland
Puzzle Medical Devices 24 Jan 2022 Health Care, Medical Device Seed Quebec, Montreal, Canada

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.